What is the current evidence for the safety and efficacy of Ribonucleic Acid (RNA) therapeutics in patients with genetic disorders or cancer?

RNA Therapeutics: Current Evidence for Safety and Efficacy

RNA therapeutics have demonstrated clinical safety and efficacy across multiple disease categories, with 30 FDA-approved products as of 2025, predominantly for genetic disorders, with the majority (two-thirds) approved since 2020 alone. 1

Approved RNA Therapeutic Categories and Clinical Applications

The FDA has approved RNA therapeutics across multiple platforms, each with distinct mechanisms and safety profiles:

Established RNA Therapeutic Platforms

• Antisense oligonucleotides (ASOs): Multiple FDA approvals for neuromuscular and metabolic disorders, with established safety profiles 1
• Small interfering RNAs (siRNA): FDA-approved since 2018, including Onpattro (patisiran) as the first approved RNAi nanomedicine for hereditary transthyretin-mediated amyloidosis 1
• Messenger RNA (mRNA): FDA-approved for COVID-19 vaccines (BioNTech/Pfizer Comirnaty and Moderna mRNA-1273), with platform technology now being applied to cancer and other viral infections 1
• Aptamers: FDA-approved for neovascular age-related macular degeneration 1
• Recombinant viral vectors: Multiple FDA approvals for genetic disorders 1

Primary Disease Indications

The majority (22 of 30 approved therapeutics) target genetic disorders, particularly neuromuscular and metabolic conditions. 1 This concentration reflects RNA therapeutics' unique ability to target previously "undruggable" proteins, transcripts, and genes 2

Safety Profile and Regulatory Framework

Regulatory Classification and Safety Considerations

The EMA and FDA do not classify mRNA vaccines against infectious diseases as gene therapeutics, despite using recombinant DNA technology, because they are transient and do not interact with the genome. 3

Critical safety considerations include:

• PEGylated lipid nanoparticles (LNPs) can potentially elicit immune responses 1
• LNPs temporarily saturate hepatic scavenging systems 1
• dsRNA impurities can trigger pro-inflammatory cytokine production and antiviral cellular states 1
• Therapeutic mRNA can act as miRNA sponges, potentially affecting endogenous regulatory pathways 1

Duration of mRNA Expression and Biodistribution

Standard modified mRNA (modRNA) typically shows expression for days to weeks, with intramuscularly administered LNP-mRNA showing no detectable liver signal after 3 days. 3

• Self-amplifying RNA platforms may demonstrate expression up to 28 days post-injection 3
• Circular RNA platforms show expression profiles up to one week 3
• Intramuscularly injected mRNA generates systemic biodistribution, including hepatic luminescence, related to LNP carriers rather than genetic integration 3

Clinical Evidence for Specific RNA Therapeutic Applications

RNAi Therapy for Primary Hyperoxaluria Type 1 (PH1)

The European Rare Kidney Disease Reference Network (ERKNet) and OxalEurope provide strong recommendations (Grade B) for RNAi therapy in genetically confirmed PH1 patients who are biochemically unresponsive to pyridoxine with urinary oxalate >1.5 times upper reference limit and active clinical disease. 1

Specific indications for RNAi therapy:

• Strong recommendation (Grade B): PH1 patients with pyridoxine-unresponsive mutations, elevated urinary oxalate, and active stone disease/nephrocalcinosis/renal impairment 1
• Strong recommendation (Grade B): PH1 patients with pyridoxine-unresponsive mutations and eGFR <30 ml/min/1.73m² 1
• Moderate recommendation (Grade B): Partial pyridoxine responders with persistent urinary oxalate elevation and clinical disease 1

The benefit of RNAi therapy must always be weighed against potential long-term risks, with annual re-evaluation of biochemical and clinical efficacy recommended. 1

Contraindications for RNAi Therapy

RNAi therapies should NOT be administered to pyridoxine-responsive PH patients with normalized urinary oxalate excretion (Grade C recommendation). 1

Delivery Systems and Formulation Strategies

Clinically Approved Formulation Approaches

Four main strategies have achieved clinical approval:

1. Chemical modification of oligonucleotides for improved pharmacokinetics 1
2. Covalent conjugation to carrier polymers (e.g., N-acetylgalactosamine conjugated siRNAs) 1
3. Encapsulation in lipid nanoparticles (Onpattro platform, COVID-19 mRNA vaccines) 1
4. Adeno-associated viral vectors for DNA delivery 1

Emerging Delivery Technologies

Dissolving microneedles (DMNs) represent an emerging platform for nucleic acid delivery, enabling tunable release kinetics, complete dissolution avoiding sharps waste, and improved cargo stability. 1

• DMNs can deliver aptamers, siRNA, mRNA, and recombinant viral vectors 1
• Plasmid DNA and viral vectors show excellent long-term stability in DMNs 1
• Further characterization needed for long RNA transcripts 1

Current Limitations and Regulatory Gaps

Critical Regulatory Deficiencies

Current regulations for preclinical biodistribution data of mRNA therapeutics are vague and ill-defined without concrete specifications on sensitivity thresholds. 1

Key regulatory inconsistencies:

• Identical mRNA compositions are classified differently: HPV mRNA for cancer treatment is classified as gene therapy, while HPV vaccination mRNA is classified as a vaccine 1
• Biodistribution studies are not strictly mandatory for non-vaccine mRNA therapeutics, despite systemic distribution 1
• Expanding clinical applications would benefit from more robust regulatory frameworks, potentially pivoting from per-product to general guidelines 1

Special Considerations for Gene Editing Applications

For mRNA delivering CRISPR/Cas9 or other gene editors, longer monitoring is required, and the risk of vertical germline transmission of induced genome modifications must be examined. 3

These applications require different regulatory oversight than standard mRNA vaccines, which do not alter genomic DNA 3

Clinical Implementation Considerations

Common Pitfalls to Avoid

• Do not assume local administration prevents systemic distribution: Intramuscular mRNA vaccines show hepatic biodistribution 1, 3
• Monitor for immune responses to PEGylated LNPs, particularly with repeated dosing 1
• Ensure dsRNA impurity testing to prevent pro-inflammatory responses 1
• Consider mRNA as potential miRNA sponges when evaluating off-target effects 1

Monitoring Requirements for RNA Therapeutics

For patients on RNAi therapy (using PH1 as exemplar):

• Measure plasma oxalate levels every 3-12 months in CKD grade 4 or higher 1
• Assess urinary oxalate and creatinine every 3-12 months depending on clinical status 1
• Annual re-evaluation of biochemical and clinical efficacy to determine continuation 1
• Kidney ultrasound at least yearly in non-dialysis patients 1

Future Directions and Emerging Evidence

RNA therapeutics are rapidly expanding beyond genetic disorders, with clinical trials evaluating safety and efficacy for cancer immunotherapy, cardiovascular disease, and infectious diseases. 4, 5

The field is evolving toward:

• Circular RNAs and self-amplifying platforms for extended expression 3
• RNA-based CRISPR/Cas9 therapies requiring enhanced biodistribution monitoring 1
• Combination approaches co-delivering nucleic acids with small molecules 1
• Non-dermal administration routes for dissolving microneedle platforms 1

The establishment of RNAi as a potent clinical modality in humans is near, with realistic optimism based on current rapid advances. 6